While patients with PDGFRA and PDGFRB fusion genes, who are receiving imatinib treatment, generally have a favorable prognosis, the advent of FGFR1 inhibitors offers hope for individuals with clonal eosinophilia and FGFR1 fusion genes. The gene discussed is FGFR1; the disease is Increased total eosinophil count.